Genomic Profiling With MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Data shows patients with MammaPrint H2 tumors have improved survival with anthracyclines, while patients with H1 tumors show no additional benefit.